Page 207«..1020..206207208209..220230..»

University of Chicago South Side Science Fest created to show off the fun, myriad pathways into field. – Chicago Tribune

Posted: September 25, 2022 at 1:59 am

Before noon on a recent Saturday, dozens of families were walking through University of Chicagos science quad, enjoying the institutions first South Side Science Festival.

A sea of the baby blue T-shirts with the word scientist on the back, walked among those with yellow tees, indicating those helping with the event. Tents housed everything from 3D printouts of CT scans of Jurassic mammal teeth and jaws, to fun with lasers by way of microwaves to immunology workshops. The number of beats per minute involved with using CPR dummies was also on the quad.

But it was the tent that offered liquid nitrogen ice cream with toppings that kept 4 -year-old Kaden Longworth engrossed.

We dont venture out of Hyde Park all that often, so the fact that its right here was so convenient, Longworth said.

And for 7-year-old Kamari Allen, it was the tent with butterflies she could sit in, that resulted in a squeal of delight.

Doctoral student Paula Fernandez, center right, teaches children about butterfly ecology inside a butterfly sanctuary at the South Side Science Festival at the University of Chicago on Sept. 17, 2022. (John J. Kim / Chicago Tribune)

The all-day, all ages event highlighted the importance of STEM education, careers in science and understanding how science impacts daily life. The festival was created to connect South Side community members with science education resources. More than 60 booths with hands-on demonstrations and experiments were on site, as were panel discussions on climate change, health and society, and a career panel where attendees could interact one on one with faculty, research scientists, engineers and medical professionals. About 200 U. of C. student volunteers, many science majors, were on hand to show off why they think science is so cool.

One booth had fifth year Tong Lan and third year Shannon Lu showcasing extracting strawberry DNA from the succulent fruit with dish soap, salt, water, and rubbing alcohol. After one student pulled out a long strand of viscous fluid red DNA with an Ewww, Lan and Lus faces light up.

Youre not the first person to say that, Lu, a chemistry major, said, laughing while mentioning strawberries have eight copies of each type of chromosome within.

Our lab does a lot of things with DNA, trying to make different engineered proteins, with this demonstration we can show people how you can take the DNA out of fruit so hopefully it will be fun and inspire the children to be a part of this, Lan said.

Shaz Rasul, executive director of student civic engagement initiatives and interim director of the University Community Service Center, said the idea of a science fest came from junior UChicago faculty. Encouraged by his office to talk to community stakeholders to get a sense of what people wanted/needed/were interested in, he said the faculty spent the good part of a year listening before starting work on it in the middle of spring.

This started during the lockdown in 2020, said Sarah King, Neubauer Family assistant professor at UChicago. Im good friends with Hannes Bernien (assistant professor of molecular engineering) and Maanasa Raghavan (Neubauer Family assistant professor of human genetics), all three of us were talking on Zoom about ways that we can interface more with our local community and get them excited, curious about science, as a way to improve our relationship with the community and also help general science education and science literacy in the general population.

Having seen the impact of Europes Long Night of Sciences, as a spring festival where universities and research institutions in Germany open their doors to the public to learn about what academics and researchers are working on, the trio wanted to do something similar.

You can go to a science concert, go to a science-based comedy thing, King said. And it is intentionally for all ages ... not just school-aged kids, but also for young adults who are in the formative years of thinking about their relationship with the world, and how science fits into that. And its their parents who are making complicated decisions about something in medicine or what car to buy, or what type of heating system to put on their house, which at the end of the day, those are all questions that are related back to science, and how you think about the world.

Those are questions that we as scientists think a lot about, and we want to help people think about those questions. But most importantly, also talk to our community about what are the things youre thinking about? What are your problems? Its a two-way street helping our research be more relevant to people and then having people have a better understanding of science in their daily lives.

Students surround a patient simulator while listening to its heartbeat during the South Side Science Festival at the University of Chicago on Sept. 17, 2022. (John J. Kim / Chicago Tribune)

The South Side Science Festival, co-organized by UChicagos physical science division, the Pritzker School of Molecular Engineering, and the biological sciences division, also served as an aid in science communication, Rasul said.

If we want the sciences to be inclusive, we have to be able to talk about them so that people at all stages in their development can connect, he said. Theres a lot of energy around the sciences right now and a lot of its around new technologies like quantum science and biotech or clean energy. Theres a real hope that if we do things differently, that all of the advancements in these new technologies can be inclusive from the start.

And we can involve communities in that whole process. Research says that people want to feel a connection to the sciences they want to meet the scientist, they want to understand how you become a scientist. Its especially important to us that we try to make those invisible pathways really visible because we want more diversity in the sciences. You need to have a connection in order to want to take a chance in it.

King hopes the South Side Science Festival becomes an annual event, connecting it to local community colleges and high schools. Shes particularly interested in the 15 to 25 age group, which is where she said people become too cool for science or think that science isnt for them.

Understanding the sciences starts with fun and excitement, said Bernien. I think thats what we are here to create.

drockett@chicagotribune.com

Big screen or home stream, takeout or dine-in, Tribune writers are here to steer you toward your next great experience. Sign up for your free weekly Eat. Watch. Do. newsletter here.

More:
University of Chicago South Side Science Fest created to show off the fun, myriad pathways into field. - Chicago Tribune

Posted in Human Genetics | Comments Off on University of Chicago South Side Science Fest created to show off the fun, myriad pathways into field. – Chicago Tribune

8 Myths About Medication Abortion and Abortion Pills – Everyday Health

Posted: September 25, 2022 at 1:58 am

Since 2020, the most common way to terminate a pregnancy in the United States is with medications rather than via a surgical procedure, according to the Guttmacher Institute. This trend has further accelerated since the COVID-19 pandemic and the growing number of restrictions on abortion in many states since the June 2022 overturning of Roe v. Wade.

Known as a medication abortion, medical abortion, or the abortion pill, the process typically involves a two-drug combination. Mifepristone, which was approved in 2000 by the U.S. Food and Drug Administration (FDA), stops pregnancy cells from growing and replicating. This pill is followed one or two days later by misoprostol, a drug that brings on heavy cramping that expels the tissue in the uterus.

Medication abortions are extremely safe and effective, says Elisa Wells, MPH, a cofounder of the abortion information website Plan C.

But myths and misconceptions about medication abortions are widespread.

Here are eight incorrect beliefs about the abortion pill, and the accurate facts everyone should know.

When we think of abortion, many of us visualize a surgical or procedural abortion, which is done in a sterile clinical setting.

A surgical abortion, per MedlinePlus, generally involves dilating the opening of the uterus, known as the cervix, and using suction to remove the fetus and other tissue from the pregnancy. Sedative medication is often used to help a person relax during the procedure. After the procedure, medicines may be given to contract the uterus and stem bleeding, along with an antibiotic to reduce infection risks.

This was once the most popular method of abortions, but in 2020 medication abortions surpassed surgical procedures for the first time, according to theGuttmacher Institute. This represents a significant increase from the groups prior research, when medical abortions accounted for 39 percent, in 2017.

This trend toward more medical abortions further increased during the COVID-19 pandemic, when surgical procedures were limited or delayed and people began looking for other options.

Medication abortion has proven to be overwhelmingly effective as well as safe during the two decades it has been in use. When the National Academies of Sciences, Engineering, and Medicine conducted a comprehensive review of the science of abortion care, it concluded that medication abortions effectively end early pregnancies with extremely low rates of serious complications.

According toPlanned Parenthood, the pills are most effective when taken at 8 weeks of pregnancy or earlier. But medication abortion still works more than 90 percent of the time for those 9 to 10 weeks pregnant, and about 87 percent of the time for people up to 11 weeks.

Even when its less effective in these later weeks of the first trimester, people can be given an extra pill, and then the abortion is almost always completed, Planned Parenthood says.

Another option in these rare cases is to follow up with an in-clinic surgical procedure to complete the abortion.

Many people confuse the abortion pill with another medication known as Plan B.

Plan B is what is known as emergency contraception. This medicine is taken soon after youve had unprotected sex to prevent you from getting pregnant.

Plan B consists of a drugstore pill that contains the hormone levonorgestrel, a synthetic progestin similar to the progesterone the body naturally makes to regulate the menstrual cycle. The hormone inhibits or delays ovulation.

Plan B can be used within 72 hours of having sex, saysSherry Ross, MD, a gynecologist and the author of She-ology and She-ology,the She-quel. It is most effective when taken within 24 hours of having sex, she notes.

By contrast, abortion pills work by a completely different mechanism, inhibiting the growth of pregnancy tissue rather than delaying ovulation. One prevents a pregnancy, and the other ends it.

Actually, you may not need to.

First, a doctor does not necessarily have to be involved. Many states allow non-physician medical professionals like physician assistants and advanced practice nurses to prescribe the pills. Some states, though, have laws requiring the person administering medication abortion to be a licensed medical doctor.

Second, during the pandemic, a growing number of telehealth medical abortion providers became available in various states. With telehealth abortions, Plan Cs Wells says, you can have this safe and effective procedure without needing to take time off work, find childcare, and the like.

Telehealth abortions allow for more privacy, since women dont have to go to an abortion clinic or navigate their way past protesters, Wells adds. And in areas of the country that are rural or underserved by providers, telehealth medication abortions can save a patient hundreds of miles of travel, according to the nonprofit Guttmacher Institute.

Plan C lists a number of these telehealth abortion sites that work in various states. They include Hey Jane, Just the Pill, Choix, Forward Midwifery, and Aid Access. You can search which telehealth providers are available in your state on the website of Plan C.

Telehealth abortions were the subject of a study published in August 2021 in Obstetrics & Gynecology. Researchers at the University of California in San Francisco followed 110 Choix telehealth patients and found 95 percent had complete abortions from the pills. The 5 percent who required further medical care is similar to the rate for in-person medical abortions, the study authors note. And no patients reported any adverse events.

Women who get the abortion pills after a telehealth consultation or who order it online take the pills in the comfort of their own home.

Even women who go to an office or clinic for a medication abortion generally take pills at home. They might take the first pill, mifepristone, in the medical setting and take the second medication home with them to take later. Or both drugs might be taken after the patient returns home.

Because it takes a while for the medicines to be effective, a medical abortion is nearly always completed in the persons home or other comfortable location.

That used to be the case, but it isnt any longer.

For a long time, mifepristone was regulated under a special provision of the FDA that required it to be administered in a clinic, hospital, or under the direct supervision of a certified medical provider, known as the in-person dispensing requirement.

This prevented it from being delivered by mail or from being readily available in retail pharmacies.

But during the pandemic the FDA changed this requirement to remove the in-person specification and added a requirement that any dispensing pharmacies must be certified. InDecember of 2021, it made the changes permanent.

Although the FDA cautions people not to buy the drugs over the internet, because you will bypass important safeguards designed to protect your health, many health experts say buying from reputable sites is fine.

The growth of online dispensing pharmacies is allowing a greater number of women to self-manage their abortion, Wells says. They simply order abortion pills directly from certain websites, without a healthcare provider prescribing it.

Plan C lists a number of dispensing pharmacies they believe are safe to order from, which varies by the state you live in. These include Secure Abortion Pills, Abortion Privacy, and Medside 24.

According toPlanned Parenthood, many health insurance plans do, in fact, cover abortions, making the procedure free or low-cost to those with this insurance. (Check with your insurance provider directly to see if your insurance is in this category.) Note that in several states, laws prohibit private insurers from covering abortion.

People on Medicaid may or may not have their abortion pills covered. Some plans in certain states cover abortion, while others dont. Some plans only cover abortion in certain cases, Planned Parenthood advises.

If your insurance wont cover the cost of a medical abortion, which can run hundreds of dollars, you may still be able to get assistance. A number of organizations offer funds to help pay for abortions. You can find some of these groups through the National Network of Abortion Funds.

Medication abortions are always legal in states that have not banned or severely restricted abortions.

In states that do have severe abortion restrictions, determining whether a medical abortion is legal can be complex.

According to theGuttmacher Institute, banning medication abortion outright has been found to be unconstitutional. But it notes that other state-level restrictions have been allowed to go into effect.

For example, South Dakota approved regulations that require patients to make four trips to a clinic in order to obtain a medication abortion, although this was blocked pending the outcome of litigation. Other states have banned the use of telehealth abortions.

Abortion advocates say some women are getting around state bans by having the medications mailed to another state where abortion pills are explicitly legal. This can be a friends address or a general delivery mailbox at a post office in that state, where the person then drives to pick up the pills.

Of course, there is a legal risk of being prosecuted in some states that prohibit medical abortions or the mailing of pills. You can learn more about the possible legal repercussions from the Repro Legal Helpline, a free site designed to educate women about their legal rights in obtaining a desired abortion.

See the article here:
8 Myths About Medication Abortion and Abortion Pills - Everyday Health

Posted in South Dakota Stem Cells | Comments Off on 8 Myths About Medication Abortion and Abortion Pills – Everyday Health

Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at…

Posted: September 25, 2022 at 1:56 am

This month, stem cell biotechnology company Asymmetrex launched a campaign to introduce the company's new online calculators for rapidly counting therapeutic tissue stem cells to cell culture core facilities at leading research colleges and universities. Today, September 20, Asymmetrex President and CEO, James L. Sherley M.D., Ph.D. will make the first introduction of the campaign in-person to users of the Cell Culture Core Facility at UMassAmherst.

BOSTON, Sept. 20, 2022 /PRNewswire-PRWeb/ -- Outside of the world of laboratory science, one of the most significant group of contributors to the excellence of U.S. biomedical research is not that well known to most people. This often-understated group is made up of the directors and technical staff of research core facilities.

Research core facilities catalyze and accelerate the research pursued by their users by providing scientific and technical expertise with the use of high-end instruments and technologies that are usually too expensive and too complex for individual research laboratories to obtain and utilize effectively on their own. Core facility personnel also play an important role in achieving the teaching mission of research institutions to train the next generations of excellent biomedical investigators.

Because of this central role in stem cell medical research played by cell culture core facilities at major research institutions, Asymmetrex selected them as the company's first focus for introduction of its new online calculators for rapid counting of therapeutic tissue stem cells. The standard research services of cell culture core facilities, including growing and counting human tissue cells, integrate directly into Asymmetrex's online portals for rapid stem cell counting.

Before Asymmetrex's technology was available, there was no method for routine, convenient counting of tissue stem cells, which are always found in mixtures with other tissue cells that obscure them from identification and counting. The need for a method to quantify tissue stem cells has significantly held back both stem cell research and stem cell medicine for more than a half century. Asymmetrex's counting technology is the first solution for this long-standing need for a means to monitor tissue stem cells in experiments and determine their dosage for more effective stem cell treatments.

Story continues

Today, September 20, Asymmetrex President and CEO, James L. Sherley, M.D., Ph.D., is presenting the new counting technology to the users of the Cell Culture Core Facility in the Institute for Applied Life Sciences at the University of Massachusetts-Amherst. His presentation will be the first seminar in the current academic year for the IALS Core Facilities Seminar Series.

The UMassAmherst core facility was the ideal choice for Asymmetrex's lead-off introduction to the capabilities and advantages of the new online stem cell calculators. Many of the validation studies for the new stem cell counting technology were performed by the UMassAmherst Cell Culture Core Facility under the direction of Michael P. Daley. Director Daley is one of the first core facility directors in the country who can now provide his users access to rapid counting of two different types of tissue stem cells widely used in stem cell research, umbilical cord blood stem cells and mesenchymal stem cells. In the future, through his core facility, faculty, students, trainees, and research staff at UMassAmherst will also be able to gain additional access to online calculators for counting many other types of important tissue stem cells used in their research.

Asymmetrex CEO Sherley has shared that he is looking forward to this first core facility introduction, which will be in-person. The company also plans a webinar series that will allow core facility directors anywhere in the U.S. to learn about doing what UMassAmherst has already started. "After UMassAmherst in-person, the first national webinar in the core facility introduction series is scheduled a week later on September 27!"

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems stem cell-specific quantification and stem cell expansion that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute|BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio). The company's development of online calculators for rapid stem cell counting has been funded by R&D grants from ARMI|BioFabUSA and the National Heart, Lung, and Blood Institute.

Media Contact

James L. Sherley, M.D., Ph.D., Asymmetrex LLC, 16179906819, jsherley@asymmetrex.com

Twitter, LinkedIn, Facebook

SOURCE Asymmetrex LLC

See the original post here:
Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at...

Posted in Massachusetts Stem Cells | Comments Off on Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at…

Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson’s Disease – SciTechDaily

Posted: September 25, 2022 at 1:55 am

Parkinsons disease is a brain condition that causes uncontrollable or unintended movements.

The immune system uses proteins referred to as antibodies to detect and attack invading pathogens. Mini versions of antibodies, called nanobodies natural compounds in the blood of animals such as llamas and sharks are being researched to treat autoimmune diseases and cancer. Now, scientists from Johns Hopkins Medicine have helped create a nanobody that can penetrate the tough outer layer of brain cells and disentangle misshapen proteins that cause disorders such as Parkinsons disease, Lewy body dementia, and other neurocognitive problems.

The structure of alpha-synuclein clumps (on the left) was disrupted by the nanobody PFFNB2 (as shown on the right). Credit: Xiaobo Mao

Researchers from Johns Hopkins Medicine, under the direction of Xiaobo Mao, Ph.D., and researchers from the University of Michigan, Ann Arbor, collaborated on the study, which was recentlypublished in the journal Nature Communications. They set out to discover a new treatment method that could target the misshapenproteins known as alpha-synuclein, which have a tendency to cluster and impede the inner workings of brain cells. New research suggests that alpha-synuclein clumps can spread from the gut or nose to the brain, accelerating disease progression.

Theoretically, antibodies may be able to target clumping alpha-synuclein proteins, but pathogen-fighting compounds have difficulty penetrating the outer covering of brain cells. To get past thetough brain cell coatings, the researchers chose to employ nanobodies, which are tiny versions of antibodies.

Traditionally, nanobodies produced outside of the cell may not perform the same function within the cell. As a result, the researchers had to strengthen the nanobodies in order for them to remain stable inside a brain cell. They achieved this by genetically engineering the nanobodies to purge them of the chemical bonds that normally degrade within a cell. Tests revealed that even without the bonds, the nanobody was still able to bind to misshapenalpha-synuclein and stay stable.

An infographic describing nanobodies. Credit: Ayanna Tucker, Joshua Glenn, and Lauren Hines

The team made seven, similar types of nanobodies, known as PFFNBs, that could bind to alpha-synuclein clumps. Of the nanobodies they created, one PFFNB2 did the best job of glomming onto alpha-synuclein clumps and not single molecules, or monomers of alpha-synuclein. Monomer versions of alpha-synuclein are not harmful and may have important functions in brain cells. The researchers also needed to determine if the PFFNB2 nanobody could remain stable and work inside brain cells. The team found that in live mouse-brain cells and tissue, PFFNB2 was stable and showed a strong affinity to alpha-synuclein clumps rather than single alpha-synuclein monomers.

Additional tests in mice showed that the PFFNB2 nanobody cannot prevent alpha-synuclein from collecting into clumps, but it can disrupt and destabilize the structure of existing clumps.

Strikingly, we induced PFFNB2 expression in the cortex, and it prevented alpha-synuclein clumps from spreading to the mouse brains cortex, the region responsible for cognition, movement, personality, and other high-order processes, says Ramhari Kumbhar, Ph.D., the co-first author, a postdoctoral fellow at the Johns Hopkins University School of Medicine.

The success of PFFNB2 in binding harmful alpha-synuclein clumps in increasingly complex environments indicates that the nanobody could be key to helping scientists study these diseases and eventually develop new treatments, says Mao, associate professor of neurology.

Reference: -Synuclein fibril-specific nanobody reduces prion-like -synuclein spreading in mice by Yemima R. Butler, Yuqing Liu, Ramhari Kumbhar, Peiran Zhao, Kundlik Gadhave, Ning Wang, Yanmei Li, Xiaobo Mao, and Wenjing Wang, 19 July 2022, Nature Communications.DOI: 10.1038/s41467-022-31787-2

The study was funded by the University of Michigan, the National Institutes of Health, the Parkinsons Foundation, and the Maryland Stem Cell Research Foundation.

View original post here:
Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson's Disease - SciTechDaily

Posted in Maryland Stem Cells | Comments Off on Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson’s Disease – SciTechDaily

QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK – Yahoo Finance

Posted: September 25, 2022 at 1:54 am

Tulsa, OK - (NewMediaWire) - September 23, 2022 - via QC Kinetix - QC Kinetix (Riverside Parkway) provides customized treatment plans to treat pain and injuries naturally and offers free consultations.

Pain from injuries, accidents, and diseases is unpleasant and potentially destructive to one's personal and professional life. Physicians often recommend surgeries and prescribe addictive pain medications when patients' pains persist. While these interventions are helpful, technological advancement and research have provided more efficient and less invasive ways of treating pain and injuries. One of the modern solutions is the use of regenerative medicine, which has a broad spectrum of minimally invasive procedures to treat mild and severe body pain.

QC Kinetix (Riverside Parkway) uses regenerative medicine to treat pain and injuries naturally. The biologic therapies help the body heal faster than normal by stimulating its natural healing abilities. In addition, the therapies strengthen the tendons, ligaments, and cartilage to avoid re-injury. These treatments are minimally invasive yet have long-lasting results to improve function and quality of life. They treat many conditions, including pain in the knee, wrists, shoulder, back, hip, and other body parts, QC Kinetix (Riverside Parkway) also has solutions for pain caused by degenerative conditions like arthritis to relieve pain and inflammation in large and smaller joints.

The pain control clinic's therapies address symptoms like limited joint mobility, stiffness, swelling, redness and warmth, knee cracking, popping, and grinding, among others. The treatments have long-lasting results and may be an alternative for knee repair and knee replacement surgeries. QC Kinetix (Riverside Parkway) offers free consultation services with one of their physicians. The consultations help patients to know whether they are eligible for regenerative medicine and inform them on the most useful therapies for their condition. During the session, the physicians investigate patients' medical history and may require additional tests to diagnose.

The treatments barely have any downtime once the healing process begins, which allows patients to get back to their normal lives faster than they would have if they had surgery. The pain control clinic provides personalized concierge-level service for logistical support for patients when receiving treatments at the facility. The physicians provide follow-up services to ensure treatments work as expected and make any necessary adjustments promptly. They keep patients informed at every step of the process, eliminating ambiguity.

QC Kinetix (Riverside Parkway) has an entire department dedicated to sports medicine to treat sports injuries like golfer's elbow, torn meniscus, torn rotator cuff, torn ACL and MCL, among others. Their sports medicine therapies are ideal when the common advice of rest, ice, compression, and elevation has failed. The clinic combines traditional sports injury treatment, rest, and bracing with regenerative medicine for optimal results. They have partnered with sports athletes like Elliot Smith, who are among the hundreds of patients that have benefited from their therapies.

The clinic has a team of board-certified physicians with extensive experience in regenerative medicine. They use advanced technologies like laser therapy and modern equipment and tools to improve the accuracy of their diagnoses and treatments. The regenerative medicine industry is among the most rapidly growing industries, and the pain control clinic has adopted a continuous learning policy that allows them to keep up to date and adapt new, evidenced techniques that can improve their patient outcomes.

The clinic representative had this to say regarding their services, "At QC Kinetix in Tulsa, OK, we are proud to offer a vast selection of regenerative treatments, helping patients of all ages avoid expensive surgeries and invasive methods. Whether your pain is due to degenerative conditions, poor body posture, repetitive movement, or a sports injury, we will find a way to relieve your symptoms and restore your movement."

The regenerative medicine provider does not believe in a one-size-fits-all approach and instead develops customized treatment plans for each patient based on their health needs. They incorporate patient values and feedback into these treatment plans and maintain a high level of engagement between them and their patients. Patients can avoid the long recovery periods and high costs commonly associated with invasive procedures through their treatments.

QC Kinetix (Riverside Parkway) is located at 9716 Riverside Pkwy, Suite 101, Tulsa, OK, 74137, US. For consultation and booking, contact their staff by calling (918) 990-9200. Visit the company website to learn more about their Tulsa office and for more information on their regenerative medicine treatments that naturally heal damaged tissues resulting in pain relief.

Media Contact:

Company Name: QC Kinetix (Riverside Parkway)

Contact Person: Scott Hoots

Phone: (918) 990-9200

Address: 9716 Riverside Pkwy, Suite 101

City: Tulsa

State: OK

Postal Code: 74137

Country: US

Website: https://qckinetix.com/tulsa/riverside-pkwy/

More here:
QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK – Yahoo Finance

Reprogramming pig cells leads way for new regenerative therapies – National Hog Farmer

Posted: September 25, 2022 at 1:54 am

A new approach is paving the way for improved stem cell therapies and regenerative applications using cells from pigs. Led by Wan-Ju Li, a SCRMC researcher and associate professor in the Department of Orthopedics and Rehabilitation and the Department of Biomedical Engineering, this new study published in Scientific Reports offers a viable strategy to enhance the generation of induced pluripotent stem cellsfrom large animal cells and provides researchers with insight into the underlying mechanism controlling the reprogramming efficiency of cells. In turn, this approach will allow researchers to reprogram cells more efficiently into iPSCs which can be used to study regenerative therapies aimed at treating everything from osteoarthritis to heart disease.

While this approach can be applied to regenerative therapies targeting any organ or tissue, Li and his Musculoskeletal Biology and Regenerative Medicine Laboratory study cartilage, so he developed the model by deriving iPSCs from the fibroblast cells of three different breeds of miniature pigs including Wisconsin miniature swine, Yucatan miniature swineand Gttingen minipigs. Fibroblast cells are easily obtained for cellular reprogramming and Li is interested in using these cells to efficiently develop cartilage cells that can be used to help patients experiencing osteoarthritis. But, while his goal for the study was specific, the model has wide-reaching implications.

"This model we created can be used for many applications," says Li. "In successfully developing iPSCs from three different breeds of minipigs, we learned we can take somatic skin cells from these pigs that we programmed ourselves into iPSCs and then inject them back into the same animal to treat the disease. Or we can take the cell that carried the disease gene and put that into the culture dish and use that as a disease model to study disease formation."

Li explained that iPSCs can be created from nearly any type of somatic cell, such as skin or blood cells, that are reprogrammed back into an embryonic-like pluripotent cells. These pluripotent stem cells are the bodys master cells and are, therefore, able to become nearly any cell in the body. Harnessing the power of such a cell and being able to grow these versatile cells in the lab is invaluable to medicine as these cells can be used for the regeneration or repair of damaged tissue and in drug testing to see how medication will impact heart, liver, or other cells within the body.

Through this research, Li and his lab have provided researchers with insight into the underlying mechanism controlling the reprogramming efficiency of iPSCs, allowing researchers to harness to power of iPSCs and develop them more efficiently. Specifically, he discovered that the expression level of the switch/sucrose nonfermentable component BAF60A, which is essentially a protein that can remodel the way DNA is packaged, helps to determine the efficiency of iPSC generation. He also noted that the BAF60A is regulated by STAT3, a transcription factor protein that plays a role in cell growth and death. Through this, Li discovered that the efficiency of iPSC generation is based on the expression level of these proteins and that the expression levels vary among pig breeds.

"While we successfully developed iPSCs and programmed iPSCs from the three different strains of pig, we noticed that some pigs had a higher reprogramming efficiency,"says Li. "So, the second part of our findings, which is significant in biology, is understanding how these differences occur and why."

Li shared that understanding why different pig breeds have varying levels of reprogramming efficiency will directly translate to understanding differences in the effectiveness of iPSC generation between individual humans. In fact, a previous study by Mackey et al., has shown that a person's ethnicity may impact their cell's reprogramming efficiency. So, understanding what mechanisms control cellular reprogramming will be crucial to developing effective protocols of iPSC generation for individualized therapies.

"With this model, we can study musculoskeletal regeneration particularly cartilage regeneration for osteoarthritis patient,"says Li. "But we think the impact is way beyond the application of orthopedics because from now on, anybody on campus who is interested in using the technology we have developed for a minipig model, can reprogram their cells into iPSCs and then these cells and the animal can be used to investigate heart disease, kidney disease, neuronal diseaseor any type of a disease."

Translating this research to improve human health, is deeply important to Li. He has spent much of his career studying novel approaches to regenerate cartilage and bone for orthopedic applications and developing a translational model like this means that science is one step closer to healing more patients using stem cells.

"I feel really touched by the stories people share. You cannot imagine how many emails come in asking me if they can become the first human patient in our future clinical trial,"Li says. "People are in desperate need for something, especially when those people feel the current surgical procedure or intervention is not suitable for them. I have to keep saying, 'wait for another two, three years, maybe we'll be ready for a clinical trial,'but for me, it's time to move on and really do our larger animal studies to fulfill our promise. At least that way, I can fill the gap between the lab and clinical trials as the larger animals must be studied before you go into a clinical trial."

Li's development of a reliable and translational model for the generation of iPSCs in a large animal is critical as it has been a challenge to generate pig iPSCs with efficiency. The reprogramming efficiency of pig cells is relatively low compared to that of human or mouse cells, but large animal studies remain a crucial step in bringing treatments to clinical trials.

Interest in moving these treatments forward has grown and while this study was funded in part by NIH, Li also received support from the Plunkett Family Foundation in Milwaukee through their donation to the UW Stem Cell and Regenerative Medicine Center. After hearing of Li's research, Gwen Plunkett and her daughter Karen visited Li and his lab in 2019 to learn more and were inspired to support research into stem cells for cartilage regeneration.

"Innovation in medicine sparks critical change, for the world and the survival of our species and the Plunkett Family mission is to be a catalyst in stem cell and regenerative medicine research,"says Karen Plunkett. "We supported Jamie Thomson's lab in the early days when federal funding for human stem cell research was restricted. More recently, we continued our commitment to this research by supporting Dr. Wan-Ju Li's stem-cell based approaches for regenerating skeletal tissues, cartilageand bone for orthopedic applications. Additionally, it is personally gratifying to be able to support the SCRMC while my son completes his senior year studying neurobiology at UWMadison.We are happy to be part of the University of Wisconsin family."

Li shared that the donation was profoundly impactful and allowed him to further his goal of using stem cells to help patients struggling with osteoarthritis as well as other joint diseases.

"I want to make sure that our findings in stem cell research can be used to help people,"says Li. "I just feel this internal drive to study this area and I feel good knowing this model carries significant weight in terms of its potential for translational stem cell research and the development of therapeutic treatments."

This research was supported by grants from the National Institutes of Health (R01 AR064803) and the Plunkett Family Foundation. The UW Department of Pathology and Laboratory Medicine and UWCCC (P30 CA014520) and the Small Animal Imaging andRadiotherapy Facility and Flow Cytometry Laboratory, supported by UWCCC (P30 CA014520) also provided facilities and services.

Source: University of Wisconsin-Madison, whichis solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsiblefor any of the contentcontained in this information asset.

Go here to read the rest:
Reprogramming pig cells leads way for new regenerative therapies - National Hog Farmer

Posted in Regenerative Medicine | Comments Off on Reprogramming pig cells leads way for new regenerative therapies – National Hog Farmer

Dr. Batcheller’s Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics – Digital Journal

Posted: September 25, 2022 at 1:54 am

Wellness and Esthetics Expert, Dr. Giselle M. Batcheller, In #1 Selling Medical Book Worldwide

Park City, Utah local and owner of Wellness and Esthetics and CARE Esthetics Utah, Dr. Giselle M. Batcheller, is featured in Quintessences 2022 #1 Selling Book Worldwide, CARE Esthetics.

Although the book was just published earlier this year, the new book written about the latest technologies in dermatology, orthopedics, regenerative medicine, and facial esthetics quickly catapulted to the number one selling spot for Quintessence.

Dr. Batcheller explains, CARE Esthetics outlines the latest technologies in regenerative medicine and facial esthetics. Quintessence historically publishes texts for doctors, yet because of the vast interest, CARE Esthetics was published for the clients of the esthetics community. That shows how highly sought after this information is.

Dr. Batcheller believes this trend will continue. Natural solutions and regenerative medicine and esthetics is a hot topic. Everyonenot just the clinicianwants to know about it. This is the future of medicine and aesthetics, and it is a very exciting future!

Dr. Batcheller provides a variety of services at Wellness and Esthetics in Park City with the most cutting edge technologies and world class equipment.

Wellness and Esthetics menu includes a variety of treatments for both health and aesthetics including PRF injections, full body (and localized) light therapy called photobiomodulation, strength-based body contouring that reduces both visceral and subcutaneous fat naturally. In addition, there are wellness enhancing laser treatments of the airway for athletic performance and Obstructive Sleep Apnea, non-surgical cavitation treatments, scar revisions, regenerative joint injections, natural treatments for non-invasive pelvic floor strengthening, and more.

Dr. Giselle M. Batcheller (DDS, NMD) and her clients are putting Park Citys Wellness and Esthetics community on the global map for advanced regenerative medicine in 2022. Dr. Batchellers passion is helping her clients look and feel their best in the most healthy and natural ways possible.

Dr. Batcheller was the first doctor in Utah to use these advanced protocols discussed in CARE Esthetics. Dr. Batcheller has been working in natural and holistic medicine since 2011. She started performing regenerative medicine and all-natural esthetics procedures with lasers and smart blood concentrate technologies in 2018. Since then, Dr. Batcheller has taught these sought after methods to dozens of prestigious doctors and providers from across the United States as well as locally throughout Utah as theyve been advancing. Dr. Batcheller has received accolades from world experts in her industry. She has been widely recognized and sought after to teach and to perform her services. She has called Park City home since 2016, and after providing these services throughout Utah and on the East Coast, shes delighted to bring her gifts to her Wellness and Esthetics office in Park City.

CARE is the acronym for the Center for Advanced Rejuvenation and Esthetics, and the book is written about a the technologies offered in CARE Esthetics centers.

Quintessence International Publishing Group is a scientific and clinical publishing company with publishing houses in 14 countries. Theyve produced more than 1,500 books from more than 3,000 authors.

Media ContactCompany Name: Wellness and Esthetics + CARE EstheticsContact Person: Dr. Giselle M. BatchellerEmail: Send EmailPhone: 833.411.4PRF (833.411.4773)Country: United StatesWebsite: https://wellnessandesthetics.com/

Continue reading here:
Dr. Batcheller's Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics - Digital Journal

Posted in Regenerative Medicine | Comments Off on Dr. Batcheller’s Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics – Digital Journal

Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More – BioSpace

Posted: September 25, 2022 at 1:54 am

This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.

Epigenetic Treatment Shows Potential in Spinal Cord Regeneration

Researchers reported that activation of the CBP/p300 protein family led to increased axon growth, regenerative signaling and synaptic plasticity in the spinal cord after injury in mice.

The study, led by Imperial College London,used a molecule called TTK21 to activate the genetic program to induce axon regeneration in neurons. During this process, TTK21 changes the epigenetic state by activating the CBP/p300 family of co-activator proteins, effectively leading to increased axon regeneration.

In the study, researchers began treating the mice 12 weeks after severe spinal cord injury and continued for 10 weeks. They found axon sprouting in the spinal cord and retraction of motor neurons above the injury. These changes are believed to have been spurred by increased gene expression related to regeneration, which the researchers attributed to the TTK21 treatment.

The results, while early and limited, are a step toward potential treatments for spinal cord injury.

The next steps will be to enhance the effects of the treatments and trigger the regenerated axons to connect to the rest of the nervous system. The ultimate goal is to enable animals, and eventually people, to regain movement lost from their injuries.

Neurological Consequences Evident in Long-Term COVID Study

In a recent attempt to decode the long-term impacts of COVID-19, researchers built a dataset fromthe national healthcare databases of the US Department of Veterans Affairs.

The study,led by the Clinical Epidemiology Center, Research and Development Service at VA St. Louis Health Care System,included154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls.

Results were published Thursday in Nature Medicine.

Upon examination of the data sets, the researchers noted an increased risk in a series of neurological consequences. These included: ischemic and hemorrhagic strokes, episodic disorders, extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain-Barr syndrome and encephalitis or encephalopathy.

They estimated a hazard ratio of 1.42 neurological sequelae per thousand COVID-19 cases, and 70.69 burdens per 1,000 cases.

These numbers were not impacted by the severity of the infection or the need for hospitalization. The researchers note the sample set comprised a majority of white men, so further exploration into other demographic groups may be necessary for future studies.

Novo Nordisk and Octagon Unite on Inflammatory R&D

Octagon Therapeutics, a pre-clinical biopharmaceutical focused on autoimmune disease, announced the initiation of a multi-year research collaboration with Novo Nordiskto studypotential treatments for inflammatory diseases.

Octagon will bring its functional target discovery approach and novel chemistry approach, while Novo will contribute its specific disease expertise.

Uli Stilz, vice president of the Bio-Innovation Hub at Novo Nordisk, commented on the synergies.

Combined with our disease understanding in the cardiometabolic space and Octagons approach in targeting specific lymphocyte populations that drive disease progression, it will be exciting to see what therapeutic discoveries the collaboration can lead to, he said.

Regen's RNA/DNA-Based Cancer Immunotherapy

Regen BioPharmaannounced the filing of a provisional patent application for its RNA/DNA-based approach to cancer immunotherapy.

The patent pertains to what Regen believes is the first combination of an immunotherapy and a gene silencing agent in a single drug.

The novel composition acts as a checkpoint inhibitor drug that also silences the genes that regulate T-cells and cancer cells such as NR2F6 and Survivin.

The new drug takes advantage of aptamers - a short RNA or DNA sequence that can also function as an antibody, recognizing specific proteins and binding to them. The proprietary sequence codes for inhibitory RNA, while keeping the aptamer intact on the other side. When it binds to a checkpoint such as PD-1, that RNA is converted within the cell, thus killing it.

Used to target cancer cells, this could lead to better disease control and treatment. There is also hope that this process could be used to activate T cells, improving their immunotherapeutic potential.

Toronto-Based Researchers Uncover Potential Solve for CAR T Toxicities

Allogeneic double-negative (DN) chimeric antigen receptor (CAR)-T cells inhibit tumor growth without off-tumor toxicities, a new study found.

Current CAR-T therapies approved by the FDA in treating blood cancers are limited by their level of toxicity and cost of production. Researchers from the Toronto General Hospital Research Institute, University Health Network, reported a new version of these therapies that did not have these drawbacks.

The researchers found healthy donor-derived allogeneic DNTs as a CAR-T cell therapy platform had high levels of efficacy in both the human and mouse models.

The researchers found the DN CAR-T cells were as effective as previously studied CAR-T cells but did not have the associated toxicity levels. They also come with the advantage of being made from mixed donors and remained effective even after being frozen for long periods of time. This feature could potentially overcome manufacturing challenges in the space.

The authors noted these features make DN CAR-T cellsan attractive off-the-shelf CAR-T cell therapy option.

See more here:
Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More - BioSpace

Posted in Regenerative Medicine | Comments Off on Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More – BioSpace

Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team – Yahoo Finance

Posted: September 25, 2022 at 1:54 am

MIAMI, FL / ACCESSWIRE / September 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has recruited a new Chief Operating Officer, Chief Information Officer, and Director of Finance.

Organicell's new Chief Operating Officer, Ryan Likes, has previously served as Co-Chief Operating Officer of Super Deluxe, a division of Turner Broadcasting, and Chief of Operations and Business Affairs of Televisa USA, the English language division of Grupo Televisa. Ryan has a juris doctorate from the Yale Law School and started his career as a corporate attorney in the Century City office of O'Melveny and Myers specializing in Mergers & Acquisitions and Finance.

Organicell's new Chief Information Officer, David Aciego, formerly served as Chief Information Officer of HTCS Corp, a managed source provider for technical services. Throughout his career,

Mr. Aciego has designed multiple systems including proprietary Enterprise Resource Planning (ERP) and Customer Relationship Management (CRP) solutions which enabled the streamlining of ordering deficiencies between different organizations and third-party distributors. Mr. Aciego has been programming since the age of seventeen and has worked with Cisco, IBM, Dell, Microsoft, Fortinet, and Meraki. Mr. Aciego served in the United States Marine Corps where he worked as an engineer on the implementation of network technologies.

Jacqueline (Jackie) Domenech, Director of Finance for Organicell, has over 10 years of Controllership experience in various healthcare and technology companies - including a recent Controller role at MD LIVE. She has successfully led transitions from outsourced accounting providers and implemented ERP systems.

Matt Sinnreich, who joined Organicell in August of 2022 as Chief Operating Officer and Acting Chief Executive Officer, will continue as President and Acting Chief Executive Officer.

Story continues

Mr. Sinnreich said, "At this stage of growth it is necessary to invest in people that can handle specific tasks and responsibilities. I am a believer in creating systems for every facet of a business that can be taught, duplicated, and scaled. I made these strategic hires to surround myself with talent with specific core-competencies in the areas of the company that needed enhancement.

Over the past few months, we have consulted with our department heads and long-term employees to identify where we as a company can improve efficiency, cut costs, and manage risk."

Sinnreich continued, "The first thing we needed was someone to help centrally manage operations and interface with our legal team. Hence, our COO hire had to be not only an experienced COO in large companies, but also a lawyer by trade. Ryan Likes has the skill sets to assist in creating processes throughout the organization and provide a completely different perspective on deal making. The deals we are working on in business development and recruiting other key additions to our team are similar in structure and milestones to talent and entertainment deals, so Ryan's experience and education will be a tremendous asset.

Next, we needed a robust Enterprise Resource Planning (ERP) system and Customer Relationship Management (CRM) system that can handle our current needs and scale with the Company's growth plan. David Aciego is running point on the development of a fully integrated, HIPAA compliant, ERP + CRM system that is currently being built on the Microsoft Dynamics platform. Data collection and management, coupled with the ability to automate Organicell's forecasting, inventory management, and staff needs, is essential in helping our company scale."

Sinnreich concluded, "Finally, our CFO needed support to better service our staff's budgetary needs to focus on the high-level compliance work and financial reporting that comes along with a publicly traded company. The Company needed systems and regulations put in place to manage and track expenses. Companies at this growth-stage rely on active and accurate cash management to expand and thrive. Jackie is highly experienced in this department with a proven track record and we believe that she will be an incredible asset to this Company."

Future Press Releases and Updates

Investors interested in receiving periodic press releases and updates are encouraged to

send an e-mail to ir@organicell.com

About Organicell Regenerative Medicines, Inc.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Investor Relations and Media Relations Contact

Organicell Investor Relations1-888-963-7881 Ext.701IR@organicell.com

SOURCE: Organicell Regenerative Medicine

View source version on accesswire.com: https://www.accesswire.com/716615/Organicell-Regenerative-Medicine-Inc-Announces-Expansion-of-Management-Team

Read this article:
Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team – Yahoo Finance

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment – Pfizer

Posted: September 25, 2022 at 1:54 am

New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Trial sites will begin to resume enrollment this month, with dosing expected to resume in October. All trial sites are anticipated to be active by the end of 2022 and a pivotal readout is expected in the first half of 2024.

About the AFFINE studyThe Phase 3 AFFINE (NCT04370054) study is an open-label, multicenter, single arm study to evaluate the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult (ages 18-64 years) male participants with moderately severe to severe hemophilia A. Eligible study participants will have completed at least six months of routine FVIII prophylaxis therapy during the lead-in Phase 3 study (NCT03587116) in order to collect pretreatment data for efficacy and selected safety parameters.

The primary endpoint is impact on annualized bleeding rate (ABR) through 15 months following treatment with giroctocogene fitelparvovec. This will be compared to ABR on prior FVIII prophylaxis replacement therapy. The secondary endpoints include FVIII activity level after the onset of steady state and through 15 months following infusion of giroctocogene fitelparvovec.

About giroctocogene fitelparvovecThe U.S. Food and Drug Administration has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to giroctocogene fitelparvovec, which also received Orphan Medicinal Product designation from the European Medicines Agency. Giroctocogene fitelparvovec is being developed as part of a collaboration agreement for the global development and commercialization of gene therapies for hemophilia A between Sangamo and Pfizer. In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug (IND) application to Pfizer. Giroctocogene fitelparvovec is currently being studied in the Phase 3 AFFINE study.

About Pfizer: Breakthroughs That Change Patients LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.Pfizer.com. In addition, to learn more, please visit us on http://www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

About Sangamo TherapeuticsSangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. To learn more, visit http://www.sangamo.com and connect with us on LinkedIn and Twitter.

Pfizer Disclosure NoticeThe information contained in this release is as of September 22, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an investigational hemophilia A therapy, giroctocogene fitelparvovec, including its potential benefits and the phase 3 AFFINE study, including anticipated timing of active trial sites, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications for any potential indications for giroctocogene fitelparvovec may be filed in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether giroctocogene fitelparvovec will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of giroctocogene fitelparvovec; uncertainties regarding the impact of COVID-19 on Pfizers business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.

Sangamo Therapeutics Disclosure NoticeThis release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding plans and timing regarding active trial sites in the Phase 3 AFFINE clinical trial, including the resumption of patient enrollment, expectations regarding the anticipated timing of dose resumption and data readouts for the Phase 3 AFFINE trial, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Sangamos actual results may differ materially and adversely from those expressed in these forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the evolving COVID-19 pandemic and its impact on the global business environment, healthcare systems and the business and operations of Sangamo and Pfizer, including the enrollment of patients and operation of clinical trials; the research and development process; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by Sangamo and Pfizer in giroctocogene fitelparvovec; the potential for Pfizer to terminate the giroctocogene fitelparvovec program or to breach or terminate its collaboration agreement with Sangamo; the potential for Sangamo to fail to realize its expected benefits of its collaboration with Pfizer; Sangamos lack of resources to fully develop, obtain regulatory approval for and commercialize its product candidate, giroctocogene fitelparvovec; and other risks and uncertainties described in Sangamo's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by Sangamos Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The information contained in this release is as of September 22, 2022, and Sangamo undertakes no duty to update forward-looking statements contained in this release except as required by applicable laws.

Pfizer Media Contact:+1 (212) 733-1226[emailprotected]

Pfizer Investor Contact:+1 (212) 733-4848[emailprotected]

Sangamo Investor Relations & Media ContactLouise Wilkie[emailprotected][emailprotected]

More:
Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment - Pfizer

Posted in Regenerative Medicine | Comments Off on Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment – Pfizer

Page 207«..1020..206207208209..220230..»